menu
    • menu
    [{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Theophylline","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Theophylline","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"PDE3\/4","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Theophylline","moa":"PDE3\/4\/A2B","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Cyrano Therapeutics \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Kyorin Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Theophylline

    Menu

    Theophylline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides Gets USFDA Nod for Theophylline Extended-Release Tablets

                            Details : Theophylline extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.

                            Product Name : Theo-Dur-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2024

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cyrano Therapeutics

                            U.S.A arrow
                            OPRD USA
                            Not Confirmed

                            Cyrano Therapeutics

                            U.S.A arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Kyorin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kyorin & Cyrano Sign Option Deal for CYR-064 in Post-Viral Smell Loss

                            Details : Under the agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064. It is being evaluated for the treatment of hyposmia.

                            Product Name : CYR-064

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Undisclosed

                            February 18, 2025

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Kyorin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cyrano Therapeutics

                            U.S.A arrow
                            OPRD USA
                            Not Confirmed

                            Cyrano Therapeutics

                            U.S.A arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cyrano Launches Study on CYR-064 for Hyposmia in Parkinson’s Patients

                            Details : CYR-064 (theophylline) is an intranasal spray works by inhibiting PDE3/4, currently being evaluated for the treatment of hyposmia in parkinson patients.

                            Product Name : CYR-064

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zydus Lifesciences

                            India arrow
                            OPRD USA
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences gets USFDA nod for asthma treatment drug

                            Details : Theophylline generic extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.

                            Product Name : Theo-Dur-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2024

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cyrano Therapeutics

                            U.S.A arrow
                            OPRD USA
                            Not Confirmed

                            Cyrano Therapeutics

                            U.S.A arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : DeepWork Capital

                            Deal Size : $9.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cyrano Therapeutics Secures $9 Million Series B Financing for CYR-064

                            Details : Cyrano aims to use proceeds to advance FLAVOR, its Phase 2 trial of CYR-064, an intranasal theophylline spray therapy for patients who lost their sense of smell after viral infections.

                            Product Name : CYR-064

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 16, 2024

                            Lead Product(s) : Theophylline

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : DeepWork Capital

                            Deal Size : $9.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth